Ask us your questions about our products, patient materials or organising a meeting.

Sanofi is here to support you and your patients

<h3>Toujeo® DoubleStar™ 
 (insulin glargine 300 units/mL)</h3>
<a href="${link:{uuid:{f34a87f8-75d0-4459-a2d8-c10d6469758f},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-combined.pdf}}}">Prescribing information UK</a>

<h3>Toujeo® SoloStar™ 
 (insulin glargine 300 units/mL)</h3>
<a href="${link:{uuid:{f34a87f8-75d0-4459-a2d8-c10d6469758f},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-combined.pdf}}}">Prescribing information UK</a>

<h3>Lantus® SoloStar™ 
 (insulin glargine 100 units/mL)</h3>
<a href="${link:{uuid:{97e86e26-07fe-49e8-b6f3-31758c4a1495},repository:{dam},path:{/Portal/UK/Prescribing-Information/Lantus_GB.pdf}}}">Prescribing information UK</a>

<h3>Trurapi® 
 (insulin aspart 100 units/mL)</h3>
<a href="${link:{uuid:{62efcdcd-db16-49b4-8041-55c212a401fa},repository:{dam},path:{/Portal/UK/Prescribing-Information/Trurapi-PI-GB-April-2023.pdf}}}">Prescribing information UK</a>

Diabetes patient support

GENERAL-MEDICINES

DIABETES-NON-CORE

DIABETES-CORE

LANTUS

TOUJEO

TYPE-1-DIABETES

TYPE-2-DIABETES

DIABETES

<h3>How to order our Vaccines</h3>
VaxiShop is Sanofi UK's streamlined vaccine ordering platform. Built specifically for healthcare professionals, it simplifies procurement across single or multiple locations, helping you order faster and more efficiently.

Access Multiple Vaccines in One Place 
 Flu, Travel &amp; Paediatric Portfolio&nbsp;

Dedicated Customer Service Team&nbsp; 
 Multichannel Support including Live Chat

Efficient Ordering 
 Enhanced Flexibility and Team Access

Increased Financial Visibility 
 Easily Review Orders and View Invoices and Credits

Account RegistrationYou will need a Sanofi account number to access VaxiShop. If you do not already have one, you can request one below &nbsp;

User RegistrationComplete our simple registration form to create your VaxiShop user profile&nbsp;

Already Registered?Existing users - If you already have a registered username, please log in with you existing username and password.

<h3 style="text-align:center;">Need Help?</h3>
Our dedicated support team is here to help you through the registration and onboarding process. Contact our Customer Services Team on <a href="mailto:GB-vaccinecustomerservices@sanofi.com">GB-vaccinecustomerservices@sanofi.com</a> or by telephone on&nbsp;<a href="tel:+0800854430" target="_blank">0800 854 430</a> (option 1)

<h2>Flu Vaccines Returns</h2>
We understand that forecasting the number of influenza vaccines you need in any given season is never easy. That's why we offer a&nbsp;"take-back service"&nbsp;giving you peace of mind that&nbsp;a percentage&nbsp;of any Sanofi flu order can be returned free of charge at the end of the flu season if it remains unused in your fridge.&nbsp;

Get in touch with the Vaccines Team

Order Smarter with VaxiShop - Your Streamlined Vaccine Ordering Platform.

The simplified eCommerce solution designed specifically for UK healthcare professionals. Save time, reduce complexity, and focus on what matters most - patient care.

How to order our Vaccines

VACCINES

VAXIGRIP

VAXIGRIP-TETRA

OTHER-VACCINES-TOPICS

<a href="${link:{uuid:{55f30477-c7e2-49c0-8cfc-16966f28d4c2},repository:{dam},path:{/Portal/UK/Prescribing-links/Praluent-PI-UK.pdf}}}" target="_blank">Prescribing Information (UK)</a>

<h2>Sanofi contracts a Homecare provider to provide homecare services free of charge</h2>
Homecare is run by experienced pharmacists who dispense Praluent®&nbsp;and arrange delivery to patients.

<ul>
 <li>In the NHS, homecare services support a range of benefits to key stakeholders</li>
 <li>Homecare services are available to individual hospitals upon signature of a Service Level Agreement</li>
</ul>
Not all hospitals will utilise our Homecare service, please confirm your own situation
Contact Details for Homecare Providers
Sciensus
✉&nbsp;&nbsp;<a href="mailto:generalenquiries@sciensus.com">generalenquiries@sciensus.com</a> 
 ☎&nbsp;&nbsp;0333 103 9499
HealthNet
✉&nbsp;&nbsp;<a href="mailto:enquiries@healthnethomecare.co.uk">enquiries@healthnethomecare.co.uk</a> 
 ☎&nbsp;&nbsp;0800 083 3060

<a href="/uk/dyslipidaemia">SEE MORE FROM SCIENCE</a>

<h3>Praluent®</h3>
Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

<h3>Patient Website</h3>
Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team

Praluent® (alirocumab) Homecare Services

Praluent® (alirocumab) Prescribing Information (UK)

FOUNDATION-NON-CORE

CV-T-CORE

ROSUVASTATIN-SANOFI

PRALUENT

ZENON

DYSLIPIDEMIA

CARDIOLOGY

<h4 style="text-align: center;"><a href="https://${link:{uuid:{3c621072-b317-4715-bb3e-c63ceb933735},repository:{dam},path:{/Portal/UK/Prescribing-links/Dupixent-AD-and-PN-GB-PI.pdf}}}" target="_blank">Dupixent (dupilumab) Prescribing Information UK</a></h4>

<h5>Disclaimer: These resources can be downloaded and must only be given to your patient(s) when the decision to prescribe DUPIXENT® has already been made by a Healthcare Professional.&nbsp; Your patient(s) must not be directed towards this website as it is intended for healthcare professionals only. However, once prescribed, patients will be given access to the patient website <a href="https://www.dupixentmyway.co.uk/ad/patient-home">www.dupixentmyway.co.uk</a> through patient materials.</h5>

<h2>Patient Support - Atopic Dermatitis</h2>
<h4>What is DUPIXENT Patient Support?</h4>
The DUPIXENT Patient Support Programme, DUPIXENT MyWay, is designed to help enrolled patients achieve optimum levels of adherence and increase levels of self-confidence and ability to manage both their condition and treatment regimen.&nbsp;&nbsp;&nbsp;
With DUPIXENT MyWay, our goal is to encourage your patients to make effective use of DUPIXENT.
With more on-demand and digital touchpoints we are giving your patients relevant tools &amp; information when they need it to support and educate them on their DUPIXENT treatment.&nbsp; 
 &nbsp;

<h3 style="color:#00A780; text-align: center;">Dispense and delivery</h3>
<ul>
 <li>Prescription management by your homecare provider</li>
 <li>They will arrange deliveries against an active prescription</li>
 <li>They will check the patient's stock when delivering and flag any medication adherence concerns</li>
</ul>

<h3 style="color:#00A780; text-align: center;">Nurse-led injection training</h3>
<ul>
 <li>Trained homecare nurses to help your patients or their carers be confident and competent in all aspects of self-administration&nbsp;</li>
 <li>Educate your DUPIXENT patients on how to get the best from the support available</li>
 <li>Virtual nursing is available for all patients</li>
</ul>

<h3 style="color:#00A780; text-align: center;">Patient support programme</h3>
<ul>
 <li>Designed to inform and motivate your patients to maintain therapy &nbsp;</li>
 <li>Including ongoing support calls, digital notifications, and injection day reminders</li>
</ul>

<h3>How to ensure your patient is signed up to the PSP</h3>
Once you have made the decision to prescribe, to ensure that your patients can benefit from all aspects of the DUPIXENT MyWay Patient Support Programme, please tick the box for PSP on the homecare registration form.

Please also give your patient or their carer the Home Delivery and Patient Support Service leaflet which can be found in the Patient Support Resource section below, designed to let your patients know what to expect from the service.

<h3 style="color:#00A780">DUPIXENT Patient Support Journey</h3>
<h4 style="color:#00A780">Homecare</h4>

<h3 style="color:#00A780">Patient Support Programme</h3>

<h3 style="color:#00A780">Injection Videos</h3>
It's important patients and carers feel comfortable and prepared for injecting DUPIXENT, so we've developed videos to help support.

<h2 style="color:#00A780">Patient Support Resources</h2>
<h3 style="color:#00A780">Patient Website</h3>
Find resources and support for your patients on DUPIXENT. This Includes information about treatment, how to inject guides, travelling with DUPIXENT information and support resources.

SPECIALTY-CARE

DUPIXENT

ATOPIC-DERMATITIS

DERMATOLOGY

<h5>All patients starting treatment on Homecare services will receive a starter pack with all of the appropriate resources above to their home.</h5>

Patient Support Resources

Paediatric Patient Support Resources

Order materials packs for your patients who are being prescribed DUPIXENT either via your local representative or Contact Medical Information on +44 (0) 800 035 2525 (Monday – Friday, 8:30-17:30, excluding public holidays).

Dupixent (dupilumab) Prescribing Information UK

DUPIXENT® (dupilumab) Atopic Dermatitis Patient Support Resources

<h4 style="text-align:center;"><a href="${link:{uuid:{d889d3ff-d4a1-4ec6-a2a0-dc62ff468d15},repository:{dam},path:{/Portal/UK/Prescribing-Information/Dupixent-Asthma-PI-GB-June-2024.pdf0}}}">Severe Asthma Prescribing Information UK</a></h4>
<h4 style="text-align:center;"><a href="${link:{uuid:{426d3c80-f750-4b27-a639-7d4c33fdecd7},repository:{dam},path:{/Portal/UK/Prescribing-Information/Dupixent-CRSwNP-PI-UK.pdf}}}">CRSwNP Prescribing Information UK</a></h4>
<h4 style="text-align:center;"><a href="${link:{uuid:{d4dafd48-4837-4ef7-ab1b-76db53f754ab},repository:{dam},path:{/Portal/UK/Prescribing-Information/Dupixent-COPD-PI-UK.pdf}}}">COPD Prescribing Information UK</a></h4>

Disclaimer: These resources should be downloaded and given to your patient(s) who have been prescribed DUPIXENT®. &nbsp;Your patient(s) must not be directed towards this website as it is intended for healthcare professionals only. However, once prescribed, patients will be given access to the patient website <a href="https://www.dupixentmyway.co.uk" target="_blank">www.dupixentmyway.co.uk</a> through patient materials.
The resources contained within this section are updated regularly by Sanofi. Before you use any of the resources, or provide any resources to your patients please re-visit this page to ensure that you are using the most up-to-date version(s).

<h2>Patient Support</h2>
<h3>What is DUPIXENT Patient Support?</h3>
Dupixent MyWay is a dedicated website for your patients that have been prescribed Dupixent.&nbsp;
The DUPIXENT Patient Support Programme, DUPIXENT MyWay, is designed for patients with the goal of encouraging your patients to make effective use of DUPIXENT.
It provides information to help support and educate patients on their DUPIXENT treatment to increase levels of self-confidence and ability to manage both their condition and treatment regimen.

<h3 style="text-align:center;">Dispense and delivery</h3>

<h3 style="text-align:center;">Nurse-led injection training</h3>

<h3 style="text-align:center;">Patient support programme</h3>

<h2 style="color: rgb(0, 167, 128);">Home Delivery and Patient Support Services</h2>

Please also give your patient or their carer the Home Delivery and Patient Support Service leaflet which can be found in the Patient Support Resource section below, designed to let your patients know what to expect from the service

<h2>Patient Support Resources</h2>
Find resources and support for your patients on DUPIXENT. This includes information about treatment, 'how to inject' guides, travelling with DUPIXENT information and support resources.

Severe Asthma - Paediatric Support Resources

IMMUNOLOGY

ASTHMA

RESPIRATORY

<h2>Patient Website</h2>
Find resources and support for your patients on DUPIXENT. This includes information about treatment, 'how to inject' guides, travelling with DUPIXENT information and support resources.

All patients starting treatment on homecare services will receive a patient pack with all of the appropriate resources to their home.
Order patient materials either via your local representative or contact Medical Information on +44 (0) 800 035 2525 (Monday-Friday, 8:30-17:30, excluding public holidays)

Learn more about Dupixent (dupilumab) for your eligible patients

Severe Asthma Prescribing Information UK

CRSwNP Prescribing Information UK

COPD Prescribing Information UK

DUPIXENT® (dupilumab) Patient Support Resources

This section has resources that you may require for your formulary submissions and business cases or policy reviews. As well as product information, therapy support resources and treatment guidelines. You can download these materials to better support your decision making.

This document provides factual and technical information about Dupixent to support relevant local formulary applications for CRSwNP.

Dupixent® (dupilumab) Formulary Application Support Pack for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Download this leave piece to understand the therapeutic value and potential cost benefits of TZIELD for payers and commissioners.

Tzield®▼ (teplizumab) Value Proposition Leave Piece

Information and guidance to support healthcare professionals and other relevant decision-makers to build a local business case for a TZIELD infusion delivery service.

Tzield 
 Business Case Template

This document supports clinical teams and service commissioners in understanding the operational requirements, patient pathways, staffing needs and logistical considerations necessary to delivery the 14-day infusion treatment safely &amp; effectively. Based on the:
<ul>
 <li>Product SmPC</li>
 <li>Expert advisory board feedback</li>
 <li>Real-world experience of TZIELD® delivery through a Managed Access Programme.</li>
</ul>

Tzield &nbsp;Service Consideration Guide &amp; Checklist

This document provides factual and technical information about TZIELD to support your understanding of the product and relevant documentation for local formulary applications.

Tzield®▼ (teplizumab) Information Guide

Case study from Birmingham, with practical, peer-to-peer insights and transferable learnings from a real-world implementation, covering how clinical, pharmacy, and nursing teams overcame operational challenges to deliver a 14-day infusion service within existing NHS infrastructure. Insights from the following healthcare professionals:
<ul>
 <li>Adults – Professor Parth Narendran</li>
 <li>Paediatrics – Renuka Dias</li>
 <li>Principal Pharmacist – Tayebah Abbasi 
 &nbsp;</li>
</ul>

Tzield Birmingham Case Study&nbsp; 
 &nbsp;

We have a range of cost models available. If you need a more detailed modelling of our basal and rapid acting insulins portfolio, please reach out to one of our representatives.

Looking for something else?

black

This document provides information on estimating patients who might be eligable for Dupixent® (dupilumab) via the COPD indication.

COPD - Eligible Population Estimator

Explore the impact that biologics could have on COPD services in regard to costs, admissions and stays within hospital.

COPD - Burden Analysis Model

An infographic showing the burden of COPD on hospital admissions, bed days and length of stay in England. For data relating to your ICB, please Get in Touch via the link below.

Burden of COPD Infographic

Get in Touch with the Health System Solutions Team

Resources to inform, aid and give insight across therapy areas, to help implement strategies to reduce inequalities in healthcare.

Formulary & Service Support

OUT-OF-TAXONOMY

PAYOR

Explore different joint working projects covering a range of disease areas, that deliver benefits to the patients, healthcare organisations and life sciences companies involved. 
Whenever possible, we publish the conclusions of our collaborative working so that others can learn from our experiences.

Sanofi undertakes collaborative working projects for the benefit of patients and/or the NHS.&nbsp;
These projects are entirely non promotional and are not linked in any way to any of our products.

Improving the pathway and experience for patients accessing the specialist Hidradenitis Suppurativa service at Salford Royal NHS Foundation trust.

Salford Royal NHS Foundation Trust Collaborative Working Project with Sanofi

A Collaborative working agreement between Sanofi and the Newcastle upon Tyne Hospitals NHS Foundation Trust to review and improve the homecare prescription pathway within the Hospital Trust

Collaborative Working Project between Sanofi and Newcastle upon Tyne Hospital Trust

Improve the patient journey and experience within the Dermatology Biologics service at Salford Care Organisation within Northern Care Alliance NHS Foundation Trust (NCA NHS FT).

Collaborative Working Project between Northern Care Alliance NHS Foundation Trust and Sanofi

This collaborative working project aims to identify areas for improvement in services, pathways, and care standards that could inform optimal utilisation of available transformation funding

St. Helens Diabetes Project

This collaborative working project aims to understand the different lipid pathways within the region, identifying the existing pressure points within services and whether inequity exists in this clinical area that contributes to overall health inequalities.

Wessex AHSN Lipid Pathway Mapping Project

A collaborative working project between University Hospitals Birmingham and Sanofi to support database creation and service improvement in severe asthma.

Collaborative Working Project between University Hospital Birmingham and Sanofi

The aim of the project is to improve patient outcomes and experiences when undergoing treatment within the BMT service in the University Hospital of Wales.

Cardiff and Vale University Health Board GvHD Project

Collaboration with healthcare organisations and the NHS to deliver real value beyond our medicines.

Let’s be Collaborative​ and Transformative

As part of our commitments around sustainability, Sanofi include carbon reduction plans in our NHS tenders, at the same time as tackling climate change and accelerating the reduction of our own environmental impact across the business.

Sanofi launched the Repen programme in 2024. This pilot programme forms part of Sanofi’s commitment to environmental protection. The used pens are posted back for recycling, free of charge to be recycled into metal, glass and plastic furniture.&nbsp;
Read more on the Repen recycling initiative that saves thousands of tonnes of waste each year.

RePen Programme

The NHS is one of the world's first healthcare systems to explicitly put sustainability in its targets which we are supporting in numerous ways.

Let’s Be Sustainable

<a href="${link:{uuid:{3c621072-b317-4715-bb3e-c63ceb933735},repository:{dam},path:{/Portal/UK/Prescribing-links/Dupixent-AD-and-PN-GB-PI.pdf}}}">Dupixent (dupilumab) Prescribing Information UK</a>
Explore our Expert Encounter series focused on Atopic Dermatitis. Uncover new strategies for managing comorbidities, learn about the latest evidence supporting disease-modifying therapies, and gain practical guidance for implementing these approaches in your clinical practice.
<h3>Exploring Disease Modification in Atopic Dermatitis: Insights from International Experts</h3>

In this enlightening Q&amp;A session, dermatology experts Professor Cork and Professor Thaçi share their valuable insights on the evolving landscape of Atopic Dermatitis treatment, with a focus on disease modification.
These videos offer valuable perspectives for Dermatologists and healthcare professionals seeking to optimise their approach to managing atopic dermatitis, particularly in cases where traditional treatments have not provided adequate control.

<h3>The Paradigm Shift in Atopic Dermatitis Management: From Control to Disease Modification</h3>

A Sanofi sponsored symposium presented at the British Association of Dermatologists Annual Meeting, July 2025
This symposium, chaired by Dr. Andrew Pink, featured insights from Professor Michael Ardern-Jones and Professor Diamant Thaçi on the evolving landscape of atopic dermatitis (AD) management. The experts discussed the transition from symptom control to disease modification in AD treatment.

Key topics included strategies for managing AD comorbidities, with a focus on ocular complications, and the latest evidence supporting the disease modification potential of targeted therapies. The faculty presented the latest data on sustained clinical control, barrier restoration, and the impact of treatment on growth, microbiome normalisation, and nerve fibre density in AD patients.
The symposium highlighted the importance of early intervention to potentially reduce cumulative life course impairment in AD. Practical guidance was provided for implementing disease-modifying therapies in clinical practice, including monitoring and managing treatment-related effects.
This paradigm shift in AD management emphasises long-term strategies for moderate-to-severe cases, aiming to alter the disease course beyond symptom control. The full recording offers in-depth discussions on these critical developments in AD care.

<h3 style="text-align:center;">Discover other resources &nbsp;</h3>

Expert Insights on Advancing the Conversation on Disease Modification in Atopic Dermatitis

DUPIXENT (dupilumab) Prescribing Information UK

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Quick Summary

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

Share via {platform} (opens email client)

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

There are no upcoming events

Showing {start}–{end} of {total} events

Event details

Check back later for upcoming events, or browse all available events across therapeutic areas.

There are no events scheduled for this therapeutic area

Something went wrong

Try a different keyword, date range, or venue.

No matching events

Registration information

Success! We've received your request

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are about to leave Sanofi campus website.

You are about to leave Campus.sanofi/uk.

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus® (nirsevimab-alip) Injection, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Title should not exceed 100 characters

Enter your title

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v7.0) - Date of Preparation: July 2025

Welcome to Sanofi Campus UK

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Resources

Diabetes patient support

How to order our Vaccines

Praluent® (alirocumab) Homecare Services

DUPIXENT® (dupilumab) Atopic Dermatitis Patient Support Resources

DUPIXENT® (dupilumab) Patient Support Resources

Formulary & Service Support

Let’s be Collaborative and Transformative

Let’s Be Sustainable

Expert Insights on Advancing the Conversation on Disease Modification in Atopic Dermatitis

Latest Resources

Diabetes patient support

How to order our Vaccines

Praluent® (alirocumab) Homecare Services

DUPIXENT® (dupilumab) Atopic Dermatitis Patient Support Resources

DUPIXENT® (dupilumab) Patient Support Resources

Formulary & Service Support

Let’s be Collaborative​ and Transformative

Let’s Be Sustainable

Expert Insights on Advancing the Conversation on Disease Modification in Atopic Dermatitis

Let’s be Collaborative and Transformative